Hormonal
Erythropoiesis-stimulating agents (epoetin alfa, epoetin beta, and darbepoetin alfa) effectively improve haematological response and reduce red blood cell transfusion requirements in cancer patients with anaemia, but do not provide a survival advantage and may increase the risk of thrombotic events.
For cancer patients with anaemia, epo drugs effectively raise hemoglobin and reduce the need for blood transfusions, improving quality of life. However, they do not extend life and may increase clotting risks. Treatment decisions should weigh these benefits against the lack of survival advantage and potential side effects, adhering to safety guidelines that limit use in patients with higher baseline hemoglobin levels.
Epo is effective in improving haematological response and reducing RBCT requirements, and appears to have a positive effect on HRQoL. The incidence of side-effects and effects on survival remains highly uncertain. ... The update, based on 28 RCTs, suggests no difference (HR 1.03, 95% CI 0.88 to 1.21).
Why this rating
Based on a systematic review of 46 RCTs and meta-analysis, though heterogeneity and missing data introduce uncertainty.
Source
The clinical effectiveness and cost-effectiveness of exercise referral schemes: a systematic review and economic evaluation
Toby Pavey et al. · Health Technology Assessment · 2011
DOI 10.3310/hta15440
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →